Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of approximately CAD3,909,600.

Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U.S. Phase I Clinical Study

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the U.S. Food and Drug Administration (“FDA”) has approved an amendment to their U.S. Phase I study, protocol LDOS001, that will accelerate the dose escalation phase …

Helix BioPharma Corp. Closes Private Placement

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD1,311,000.

Helix BioPharma Corp. Peer Review Publication of VDOS47

(Richmond Hill, Ontario) – Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the publication of a peered-reviewed V-DOS47 manuscript in “Frontiers in Immunology” journal. V-DOS47 is Helix’s second DOS47 development candidate following L-DOS47, which is currently in clinical testing …